Intense Drafting Session Ahead For WIPO Delegates Working On Genetic Resources 01/02/2013 by Catherine Saez, Intellectual Property Watch 2 Comments Next week, World Intellectual Property Organization delegates will convene for the first committee meeting of 2013. First up is the protection of genetic resources from misappropriation, and the goal of the week is to bridge gaps so they can construct a text that could become an international instrument on protection.
Genetic Resources And Traditional Knowledge : Getting The Rules Right For Agriculture: A Key Challenge For WIPO’s IGC 01/02/2013 by Intellectual Property Watch 4 Comments An essential relationship exists among the conservation, development and use of genetic resources, sustainable agriculture and food security. There is an equally essential relationship between the conservation, development and use of genetic resources and small scale-farmers. The strength and effectiveness of any treaty addressing IP and genetic resources depends on the meaningful participation of small-scale farmers, and those that can represent them, as in the treaty deliberations continuing next week at WIPO, write Susan Bragdon and Lynn Finnegan.
UNIGE Panel Promotes Advantages Of Trade Secret Protection 31/01/2013 by Tiphaine Nunzia Caulier for Intellectual Property Watch Leave a Comment Intellectual property professionals speaking at the University of Geneva last week discussed the challenges faced by companies and legislators in the domain of trade secrets. Topics addressed included the impact globalisation has on the protection of trade secrets, the need for an harmonised regime at the European level, and the need to rethink the place of trade secrets in the current international IP regime.
Potential Elements Of The WHO Global R&D Treaty: Tailoring Solutions For Disparate Contexts 29/01/2013 by Intellectual Property Watch 1 Comment Prof. Ryan Abbott analyzes the key components of the WHO proposal for a Global R&D Treaty and their potential impact on public health. The article proposes strategies to convert parties currently opposing the treaty, and argues that a stratified limited market-exclusivity regime has the capacity for a meaningful impact.
Debate Erupts At WHO Over “Consensus” On Financing R&D For The Poor 28/01/2013 by William New, Intellectual Property Watch 5 Comments World Health Organization members on Friday held a tense discussion over legal and political aspects of a consensus reached by a small number of member states in November on implementing a plan to address the global lack of research and development for neglected diseases predominantly afflicting poor populations. The discussion may continue today, with the linkage of an agenda item on neglected tropical diseases and the report of an expert working group offering numerous ideas for addressing the problem.
WHO Plan For Pandemic Flu Proceeds With Questions 28/01/2013 by William New, Intellectual Property Watch 3 Comments The World Health Organization has not completed negotiations with companies on a formula for contribute toward the new WHO framework for pandemic influenza. But companies are paying to access the virus anyway. In its meeting this week, the WHO Executive Board has addressed a range of issues such as pandemic influenza, but so far it has delayed discussion on another contentious topic: substandard/counterfeit medical products.
IP Professionals Discuss Tech Transfer Potential In Humanitarian Business At WIPO 23/01/2013 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment A global business association held a meeting at the World Intellectual Property Organization this week on IP market developments, including increasing opportunities in technology transfer for commercial purposes. The intimate gathering featured a line-up of high-level speakers, including WIPO Director General Francis Gurry.
2013: India Battles For Right To Use Compulsory Licences To Make Medicines Affordable 22/01/2013 by Patralekha Chatterjee for Intellectual Property Watch Leave a Comment India has started the New Year on a volatile note. With general elections looming in 2014, there is turbulence and not just in the political world. In India’s pharmaceutical industry, there is sparring over the prickly issue of ‘compulsory licenses’, a mechanism by which a government allows a domestic company to manufacture and sell a generic version of a patented drug without the consent of the patent-holder, who receives compensation.
2013: The Year Ahead In IP Policy The annual Intellectual Property Watch Year Ahead series examines the trends in 2013 related to international policy in public health, IP law, copyright/access to knowledge, biotech/biodiversity, internet governance, trade, and other intellectual property rights issues. Note: IP-Watch subscription is required to access Year Ahead stories for the first six months. Click here for details. Global […]
US FTC Finds Sharp Rise In ‘Pay-For-Delay’ Deals Blocking Generics 18/01/2013 by William New, Intellectual Property Watch 2 Comments The United States Federal Trade Commission, which keeps an eye out for anticompetitive behaviour, has issued a study finding that in 2012, a record number of deals were struck between brand-name and generic drug companies to keep the lower-priced generics off the market. Such deals, which arise from patent disputes, cost American consumers billions of dollars annually while piling on the federal deficit, it said.